Sociedad Americana de Hirudoterapia

An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent

Research article published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (1991)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosEnsayos clínicosFareed J et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991

Abstract

Leeches have been in medical use for many years. Hirudin, the anticoagulant obtained from the medicinal leech has been purified, characterized and can now be produced by recombinant (r) technology. R-hirudin is a potent inhibitor of thrombin and is therefore a potentially valuable anticoagulant and antithrombotic drug. This article reviews the current status of r-hirudin in this role and compares the pharmacokinetics, mechanism of action and clinical efficacy of this agent with heparin. The methods available for laboratory assessment and clinical monitoring of r-hirudin and the possible ways of antagonizing its effects are also discussed. Finally, the potential clinical applications of r-hirudin are outlined, although further laboratory and clinical studies, together with a fall in the cost of this compound are required before r-hirudin can be more widely accepted as an anticoagulant and antithrombotic agent.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAmino Acid SequenceAnimalsBlood CoagulationBlood PlateletsDrug EvaluationFibrinolytic AgentsHemorrhageHeparinHirudin TherapyHirudinsHumansMolecular Sequence Data

Resumen

Leeches have been in medical use for many years. Hirudin, the anticoagulant obtained from the medicinal leech has been purified, characterized and can now be produced by recombinant (r) technology.

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.

Fareed J et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent | ASH